stacks-image-8ef2dbd.png

Kevin Ness, CEO

Kevin specializes in rapidly commercializing early stage ideas into successful ventures. He has extensive experience in the innovation, development, and launch of novel technologies to develop new paradigms to measure complex biological information at unprecedented resolution. He previously co-founded QuantaLife and then 10x Genomics, helping bring to the world ddPCR, Linked-Read sequencing, and massively parallel single cell solutions. As a mechanical engineer, he is a true tool builder at heart, and has committed his life to building the best-in-class tools, chemistries and software for biologists..

stacks-image-104a9f0.png

Ryan T Gill, CSO & Co-Founder

Ryan is a co-founder of Muse bio and has established his career at the forefront of developing new genome engineering technologies. He has founded multiple successful technology start-ups across a broad application space. Ryan brings a strong background in corporate strategy, technology development, and intellectual property. Ryan was a key inventor of Muse bio’s foundational technology, which was developed at the University of Colorado, Boulder where he is the Slade Professor, Chemical and Biological Engineering and Executive Director of the BioDesign Center at the RAS Energy Institute. Ryan’s academic research focus bridges metabolic engineering and synthetic biology with a particular emphasis on the development of new engineering tools and technologies.

stacks-image-fbecba3.png

Tanya Lipscomb, CTO, VP R&D, Co-founder

Tanya is a co-founder of Muse bio. She is an expert at managing complex technical programs and building high-performance teams. She has a proven track record of delivering success against cross-functional engineering projects, including multi-million dollar efforts focused on cost competitive biochemical production. Prior to Muse bio, Tanya oversaw the Metabolic Engineering and Genomics efforts at OPXBIO and was a key inventor on the core R&D innovation.

stacks-image-4e3d050.png

Erik Warneke, VP Finance

Erik has an extensive financial and accounting background spanning fifteen years and specializes in turning complex financial data into meaningful information for effecting decision making. He has built high-performing teams to provide robust, effective analysis and reporting at each step in his career. His expertise includes financing, controls and compliance, finance and treasury management, SEC and financial reporting and investor relations. Prior to Muse bio, Erik served as Controller at Metropolitan Merchant Capital and played a senior financial reporting role during ZAYO’s IPO in 2014. Erik began his career in public accounting at Ernst & Young. He earned B.S. degrees in Accounting and Finance at Indiana University-Bloomington and his CPA certification in 2002.

AAEAAQAAAAAAAASbAAAAJDQ1ZjUzZmY1LTcwYjctNGMwNi1hZGFhLTNkODAxMTU0ZmU5ZA.jpg

Dianna DeVore, General Counsel

Dianna is General Counsel of Muse, specializing in product protection strategies, transactional law and patent enforcement for life science companies.  Dianna was previously Senior Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc., acquired by Roche Molecular Systems in 2015. Dianna has been legal and IP counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Elan Pharmaceuticals. In 2002, Dianna co-founded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence.  At the ASCC, Dianna was responsible for oversight of all operational, corporate, legal and intellectual property activities of the ASCC. 

Jason Mug.jpg

Jason Amsbaugh, Senior Director of Marketing

Jason is Senior Director of Marketing at Muse Bio.   With significant experience in both strategic and tactical marketing, he excels at identifying new markets and building out sales funnels to achieve business objectives.   Previously, he served as Director of Global Marketing at ArcherDX, where he oversaw commercialization of NGS-based tumor profiling assays.